Abstract 13465: Tirzepatide vs. Semaglutide for Secondary Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus With an Initial HbA1c of >8.5 - A Value for Money Analysis

Authors: Joseph Azuri, Enis Aboalhasan, Ben Sluckis, Ariel Hammerman, Ronen Arbel

Published: 2023-12-19